Home › NDC Lookup › RxCUI directory › RxCUI 2106343

Amifampridine 10 MG Oral Tablet — RxCUI 2106343

RxNorm drug concept · Semantic clinical drug
RxCUI 2106343 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2106343
Official nameAmifampridine 10 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asamifampridine 10 MG (as amifampridine phosphate 18.98 MG) Oral Tablet
FDA products mapped1
Package NDCs mapped3
Reported Medicaid activity (SDUD)211 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Amifampridine 10 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Amifampridine 10 MG Oral Tablet RxCUI 2106343

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Amifampridine 2106338
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Firdapse 2107513
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Amifampridine Oral Tablet 2106342
    • Amifampridine Oral Product 2106340
    • Amifampridine Pill 2106341
    • Amifampridine Oral Tablet [Firdapse] 2107515
    • Firdapse Oral Product 2107516
    • Firdapse Pill 2107517
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Amifampridine 10 MG SCDC · 2106339
  • Amifampridine Oral Tablet SCDF · 2106342
  • Amifampridine Oral Product SCDG · 2106340
  • Amifampridine Pill SCDG · 2106341

Brand-Name Concepts

  • Amifampridine 10 MG Oral Tablet [Firdapse] SBD · 2107518
  • Amifampridine 10 MG [Firdapse] SBDC · 2107514
  • Amifampridine Oral Tablet [Firdapse] SBDF · 2107515
  • Firdapse Oral Product SBDG · 2107516
  • Firdapse Pill SBDG · 2107517
  • Firdapse BN · 2107513

📦 FDA Products & Package NDCs

1 product · 3 package NDCs
3 package NDCs map to RxCUI 2106343 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
69616-0211-03 240 TABLET in 1 BOTTLE, PLASTIC (69616-211-03) Firdapse Catalyst Pharmaceuticals, Inc. 2019-01-07
69616-0211-06 12 BLISTER PACK in 1 CARTON (69616-211-06) / 10 TABLET in 1... Firdapse Catalyst Pharmaceuticals, Inc. 2019-01-07
69616-0211-08 60 TABLET in 1 BOTTLE, PLASTIC (69616-211-08) Firdapse Catalyst Pharmaceuticals, Inc. 2019-01-07
Observed labelers: Catalyst Pharmaceuticals, Inc. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.